ERIS · NSE
Eris Lifesciences Limited
₹1,317.2
-0.89% (-₹11.8)
Prev. close
₹1,329
Volume
33,292
Delivery %
32.9%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Eris Lifesciences with a target price of ₹1975. The call implies a bullish outlook on the stock.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Eris Lifesciences | MISS | |
| “Bullish on Eris Lifesciences due to strong financial performance, growth prospects, market position, and operational eff…” | Marketsmith India AnalysisMarketsmith India | Eris Lifesciences Ltd | HIT | |
| “Recommends buying Eris Lifesciences Ltd. at ₹1,493.5 with a target price of ₹1,690 in three months and a stop loss at ₹1…” | Marketsmith India AnalysisMarketsmith India | Eris Lifesciences Ltd. | HIT | |
| “Bullish on Eris Lifesciences, recommending a buy at ₹1340.7 with a target of ₹1420 and a stop loss at ₹1290 for intraday…” | Sumeet BagadiaChoice Equity Broking | Eris Lifesciences Ltd | MISS | |
| “Recommends buying Eris Lifesciences with a target price of ₹1450. The call implies a bullish outlook on the stock.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Eris Lifesciences | PENDING | |
| “Bullish on Eris Lifesciences for the next 2-3 weeks, targeting ₹1,400. The stock is at a key support level within its co…” | Vishnu Kant UpadhyayMaster Capital Services | Eris Lifesciences | MISS | |
| “Bullish on Eris Lifesciences with a target of ₹1,700, suggesting a 28% upside. The company targets ₹3,000 crore revenue …” | Ashika Institutional Equities AnalysisAshika Institutional Equities | Eris Lifesciences Ltd | PENDING |
Fundamentals
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, GLP-1, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram monitoring, continuous glucose monitoring system, sleep device, antenatal care, and early neuropathy screening solutions, as well as polycystic ovary syndrome screening, diagnosis, and management. The company offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Amit Indubhushan Bakshi
Headquarters
Ahmedabad
Employees
2,758
Website
eris.co.inExchange
View on NSE ↗Key stats
Market cap
₹16,654.18 Cr
P/E ratio (TTM)
23.7
Dividend yield
1.22%
EPS (TTM)
₹50.66
Beta (1Y · daily vs NIFTY 50)
0.55
Beta (5Y · monthly vs NIFTY 50)
0.70
Shares float
4.43 Cr
EPS · quarter ended Sept 2026
₹13.25
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,211.86 Cr | ₹1,347.04 Cr | ₹1,685.15 Cr | ₹2,009.14 Cr | ₹2,893.64 Cr | ₹3,129.42 Cr | |
EBITDA | ₹439.28 Cr | ₹511.05 Cr | ₹547.90 Cr | ₹698.65 Cr | ₹1,035.56 Cr | ₹1,110.62 Cr |
| ₹355.14 Cr | ₹406.11 Cr | ₹382.16 Cr | ₹391.98 Cr | ₹351.84 Cr | ₹619.52 Cr | |
Diluted EPS | ₹26.14 | ₹29.88 | ₹28.07 | ₹28.79 | ₹25.81 | ₹45.26 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,834.78 Cr | ₹2,272.14 Cr | ₹3,667.33 Cr | ₹7,048.84 Cr | ₹7,033.17 Cr | ₹7,365.51 Cr | |
| ₹6.78 Cr | ₹84.41 Cr | ₹876.71 Cr | ₹2,781.28 Cr | ₹2,477.92 Cr | ₹2,358.62 Cr | |
Stockholders' equity | ₹1,577.00 Cr | ₹1,909.00 Cr | ₹2,196.00 Cr | ₹2,587.00 Cr | ₹2,855.00 Cr | ₹3,903.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹375.00 Cr | ₹378.00 Cr | ₹292.00 Cr | ₹486.00 Cr | ₹1,065.00 Cr | ₹538.00 Cr | |
Investing cash flow | ₹-323.36 Cr | ₹-319.61 Cr | ₹-974.61 Cr | ₹-1,854.52 Cr | ₹-79.97 Cr | ₹-369.46 Cr |
| ₹-82.00 Cr | ₹-45.00 Cr | ₹688.00 Cr | ₹1,380.00 Cr | ₹-881.00 Cr | ₹-314.00 Cr | |
Capital expenditure | ₹-26.00 Cr | ₹-121.00 Cr | ₹-841.00 Cr | ₹-129.00 Cr | ₹-155.00 Cr | ₹-297.00 Cr |
End cash position | ₹36.92 Cr | ₹50.87 Cr | ₹56.02 Cr | ₹94.25 Cr | ₹199.74 Cr | ₹54.74 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 17–Jun 18(6Q) | Sep 18 | Dec 18 | Mar 19 | Jun 19–Dec 19(3Q) | Mar 20–Jun 20(2Q) | Sep 20 | Dec 20 | Mar 21 | Jun 21 | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22 | Dec 22 | Mar 23–Jun 23(2Q) | Sep 23 | Dec 23–Mar 24(2Q) | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.93% | 55.92% | 56.04% | 56.10% | 56.23% | 55.55% | 54.08% | 54.23% | 54.13% | 52.69% | 52.68% | 52.66% | 52.30% | 52.29% | 52.70% | 52.86% | 54.91% | 54.90% | 54.88% | 54.87% | 54.86% | 54.85% | 54.83% | 54.85% | 53.92% | 54.14% |
| Public | 44.07% | 44.08% | 43.96% | 43.90% | 43.77% | 44.45% | 45.92% | 45.77% | 45.87% | 47.31% | 47.32% | 47.34% | 47.70% | 47.71% | 47.30% | 47.14% | 45.09% | 45.10% | 45.12% | 45.13% | 45.14% | 45.15% | 45.17% | 45.15% | 46.08% | 45.86% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Eris Lifesciences Limited | ₹16,654.18 Cr | ₹1,215 | 23.7 | 4.27 | 15.9% | 0.60 | +8.2% | -24.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Eris Lifesciences expects 150-200 bps margin improvement in H2 as biologics scale up
CNBC TV18 · 26 days ago
Eris Lifesciences Files Scrutinizer’s Report and Voting Results for 20th AGM
Eris Lifesciences Ltd submitted the scrutinizer’s report and voting results for its 20th Annual General Meeting, held on September 25, 2026. Shareholders participated through remote e-voting and electronic voting. This action reflects the company's compliance with corporate governance and regulatory requirements.